|
CCDC75 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62492241884138E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.30149233004795E-13 |
| Normal-vs-Stage2 |
2.47650000506638E-08 |
| Normal-vs-Stage3 |
1.64390723256247E-12 |
| Normal-vs-Stage4 |
9.14730002854469E-09 |
| Stage1-vs-Stage2 |
6.211200E-01 |
| Stage1-vs-Stage3 |
2.984200E-01 |
| Stage1-vs-Stage4 |
4.972600E-01 |
| Stage2-vs-Stage3 |
8.065200E-01 |
| Stage2-vs-Stage4 |
8.959800E-01 |
| Stage3-vs-Stage4 |
9.288800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.66133814775094E-15 |
| Normal-vs-AfricanAmerican |
1.44800000001499E-06 |
| Normal-vs-Asian |
4.51110000021515E-07 |
| Caucasian-vs-AfricanAmerican |
8.753600E-01 |
| Caucasian-vs-Asian |
6.068200E-01 |
| AfricanAmerican-vs-Asian |
6.384600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.44089209850063E-16 |
| Normal-vs-Female |
1.87649895622144E-12 |
| Male-vs-Female |
2.068200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.72459824199223E-11 |
| Normal-vs-Age(41-60Yrs) |
1.23789867245705E-13 |
| Normal-vs-Age(61-80Yrs) |
6.31109609017244E-11 |
| Normal-vs-Age(81-100Yrs) |
1.028420E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.170800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.769400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.419800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.487000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.171800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.789400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.893800E-01 |
| Classical-VS-Follicular |
7.696200E-02 |
| Classical-VS-Other |
1.020610E-01 |
| Classical-VS-Normal |
2.29904983939377E-12 |
| Tall-VS-Follicular |
7.941200E-01 |
| Tall-VS-Other |
2.430200E-01 |
| Tall-VS-Normal |
3.75589999990211E-07 |
| Follicular-VS-Other |
3.280800E-01 |
| Follicular-VS-Normal |
2.39299691173755E-11 |
| Other-VS-Normal |
1.771790E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.26245713672324E-14 |
| Normal-vs-N1 |
5.52619949800714E-10 |
| N0-vs-N1 |
3.673600E-01 |
|
|
